Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab plus rapid glucocorticoid taper versus placebo in polymyalgia rheumatica
2016-004990-42Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Tocilizumab plus rapid glucocorticoid taper with Placebo plus rapid glucocorticoid taper (2 arms). Primary endpoint: Proportion of subjects in glucocorticoid-free remission at week 16. Started Aug 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2016-004990-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004990-42.